Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.19.2
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Antidilutive securities excluded from computation of diluted weighted shares outstanding 25,418,970 22,559,840
Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 5,803,529 3,082,032
Unit Purchase Options - "UPO-Z" /"UPO-W" - as to Shares of common stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000 53,000
Unit Purchase Options - "UPO-Z" - as to Shares Underlying Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000
Unit Purchase Options - "UPO-W" - as to Shares Underlying Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000
Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 16,815,039 16,815,039
Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 381,818 381,818
Series S Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 1,199,383 1,199,383
Series B Convertible Preferred Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 1,113,201 975,568